We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

97 hedge funds and large institutions have $441M invested in CytomX Therapeutics in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 16 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 16

53% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 15

29% more capital invested

Capital invested by funds: $343M → $441M (+$98M)

8% more funds holding

Funds holding: 90 → 97 (+7)

5.6% more ownership

Funds ownership: 60.15% → 65.75% (+5.6%)

0% more call options, than puts

Call options by funds: $1K | Put options by funds: $1K

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
97
Holders Change
+7
Holders Change %
+7.78%
% of All Funds
2.42%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
23
Increased
38
Reduced
16
Closed
15
Calls
$1K
Puts
$1K
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$8.15M
2
State Street
State Street
Massachusetts
+$6.36M
3
BlackRock
BlackRock
New York
+$3.86M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.5M
5
BI
BVF Inc
California
+$3.18M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$4.93M
2
DCM
Driehaus Capital Management
Illinois
-$4.5M
3
VMI
VHCP Management II
New York
-$4.48M
4
EAM
Eventide Asset Management
Massachusetts
-$2.33M
5
CAM
Cormorant Asset Management
Massachusetts
-$2.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$100M +$275K +17,646 +0.3%
BI
2
BVF Inc
California
$40.5M +$3.18M +203,900 +10%
BlackRock
3
BlackRock
New York
$37.4M +$3.86M +247,389 +14%
PA
4
Perceptive Advisors
New York
$25.3M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$20.9M +$3.5M +224,068 +24%
State Street
6
State Street
Massachusetts
$15.5M +$6.36M +407,703 +91%
EC
7
EcoR1 Capital
California
$15.1M +$543K +34,802 +4%
DM
8
Deerfield Management
New York
$13.8M – – –
Millennium Management
9
Millennium Management
New York
$11.4M +$8.15M +522,495 +510%
Renaissance Technologies
10
Renaissance Technologies
New York
$9.77M +$1.98M +127,000 +31%
NI
11
Numeric Investors
Massachusetts
$9.72M -$1.45M -92,905 -15%
TCM
12
Tekla Capital Management
Massachusetts
$9.63M – – –
OM
13
Opaleye Management
Massachusetts
$8.18M -$156K -10,000 -2%
RG
14
Redmile Group
California
$6.95M -$4.93M -316,121 -45%
Franklin Resources
15
Franklin Resources
California
$6.06M – – –
Northern Trust
16
Northern Trust
Illinois
$5.99M +$202K +12,925 +4%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$5.92M +$1.42M +91,162 +39%
Goldman Sachs
18
Goldman Sachs
New York
$5.91M +$3.08M +197,389 +154%
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$5.63M +$1.05M +67,393 +28%
TCIM
20
TIAA CREF Investment Management
New York
$4.32M +$1.06M +68,147 +40%
JP Morgan Chase
21
JP Morgan Chase
New York
$4.31M -$65.5K -4,200 -2%
SIM
22
Spark Investment Management
New York
$4.3M – – –
SFM
23
Sphera Funds Management
Israel
$3.82M +$156K +10,000 +5%
PAG
24
Private Advisor Group
New Jersey
$3.66M +$1.33M +85,187 +85%
Deutsche Bank
25
Deutsche Bank
Germany
$3.6M +$1.45M +93,048 +88%
1
2 3 4 5

CTMX Hedge Fund Activity: Q3 2017 in Review

97 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2017, worth a combined $441M — up 29% from $343M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CTMX positions and 15 closed out — a net gain of 8 holders — while 38 added to existing stakes and 16 trimmed.

The largest buyer was Millennium Management, adding an estimated $8.15M. The largest seller was Redmile Group, cutting an estimated $4.93M.

  • 97 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2017, up from 90 in Q2 2017.
  • Funds reported $441M of CytomX Therapeutics stock for Q3 2017, up 29% quarter-over-quarter.
  • 23 funds opened new CytomX Therapeutics positions in Q3 2017 and 15 closed out, a net change of +8 holders.
  • The largest CytomX Therapeutics buyer in Q3 2017 was Millennium Management, an estimated $8.15M added.
  • The largest CytomX Therapeutics seller in Q3 2017 was Redmile Group, an estimated $4.93M sold.

Based on aggregated 13F filings for Q3 2017.